Drug | Disease | Trial | Any-grade neurotoxicity (%)* | Grade ≥3 neurotoxicity (%) | Steroids mandated for NT in trial protocol? |
Axicabtagene ciloleucel[1,2] | DLBCL | ZUMA-1 | 64 | 28 | Yes |
FL | ZUMA-5 | 77 | 11 | Yes | |
Brexucabtagene autoleucel[3] | MCL | ZUMA-2 | 63 | 31 | Yes |
Ciltacabtagene autoleucel[4] | MM | CARTITUDE-1 | 17 | 2 | Yes |
Idecabtagene vicleucel[5] | MM | KarMMa | 18 | 3 | Yes |
Lisocabtagene maraleucel[6] | DLBCL | TRANSEND NHL 001 | 30 | 10 | Yes |
Tisagenlecleucel[7,8] | DLBCL | JULIET | 21 | 12 | No |
B-ALL | ELIANA | 40 | 13 | No |
CAR-T: chimeric antigen receptor T; NT: neurotoxicity; DLBCL: diffuse large B cell lymphoma; CTCAE: Common Terminology Criteria for Adverse Events; FL: follicular lymphoma; MCL: mantle cell lymphoma; MM: multiple myeloma; B-ALL: B cell acute lymphoblastic leukemia; ASTCT: American Society for Transplantation and Cellular Therapy.
* Using CTCAE 4.03 grading system for neurotoxicity for all products except ciltacabtagene autoleucel, which used CTCAE 5.0 in phase 1b and ASTCT ICANS criteria in phase 2.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟